CA-TRICENTIS
Tricentis, the leader in continuous testing for DevOps, announced that it has acquired SpecFlow, the biggest and most trusted BDD solution for .NET developers around the world. SpecFlow’s pragmatic approach to specification-by-example has helped agile development teams improve collaboration with business stakeholders to build and deliver higher quality software.
SpecFlow will continue to remain a free, open source offering for the software development and testing communities. SpecFlow+ , SpecFlow’s commercial offering, and SpecMap , an Azure DevOps extension for user story mapping, will now be offered for free to meet the needs of scaling BDD across the enterprise – all backed by Tricentis’ leading innovation in continuous testing.
With this acquisition, Tricentis continues to extend its leadership in the open source and developer-led testing market. SpecFlow is Tricentis’ second acquisition in this market within the past year, with further acquisitions planned in the coming months. In 2019, Tricentis acquired TestProject , the world’s first free, cloud based test automation platform leveraging Selenium and Appium. The acquisition of SpecFlow adds best-in-class support for BDD and .NET developers to round out Tricentis’ comprehensive open source testing platform.
“BDD is becoming broadly relevant in enterprises for their digital transformation,” explained Tricentis Founder and Chief Strategy Officer Wolfgang Platz. “As business requirements change at DevOps speed, teams need a way to document how their applications should behave across highly integrated systems. Without built-in test automation to this shared understanding, software delivery leads to production bugs and poor user experiences. SpecFlow’s ability to create this shared business understanding, connected with automated tests, makes it the most trusted BDD platform for .NET development.”
SpecFlow was developed by TechTalk as the open source port of Cucumber for .NET in 2009. Since then, SpecFlow has gathered a massive open source community, with more than 9.6 million downloads and a user base that continues to grow at more than 3,000 downloads per day.
SpecFlow provides a way to define, manage and automatically execute human-readable acceptance tests in .NET projects. By using human-readable syntax, known as Gherkin (“Given-When-Then”), SpecFlow helps software delivery teams to create a common business understanding of how their systems should behave. Its integration with popular developer tools like Selenium and Microsoft Visual Studio have made SpecFlow the BDD standard to bridge the communication gap between developers, testers and business users.
“I’m extremely proud of the community that SpecFlow has fostered over the years,” said Christian Hassa, Owner and Managing Partner at TechTalk. “TechTalk is happy to have found a partner in Tricentis who is committed to the BDD community and to significantly expand on our vision for SpecFlow while keeping it independent.”
About SpecFlow
SpecFlow is the world’s leading open-source Behavior-Driven Development framework for .NET. SpecFlow facilitates collaboration between teams in small and large enterprises, allows you to automate tests written in human-readable language, and helps stakeholders build up a shared understanding of software systems. Learn more about SpecFlow at https://specflow.org .
About TechTalk
TechTalk is a Central European company that specializes in agile methods, agile development, and agile coaching. TechTalk was a first mover in the agile community, realized the potential of Behavior-Driven Development at an early stage and started developing SpecFlow in 2008. TechTalk released SpecFlow as an open-source project in 2009 to involve the agile community and accelerate the growth and adoption of SpecFlow. Learn more about TechTalk at https://techtalk.at or follow us on LinkedIn , Twitter .
About Tricentis
With the industry’s #1 Continuous Testing platform, Tricentis is recognized for reinventing software testing for DevOps. Through agile test management and advanced test automation optimized to support over 150+ technologies, we provide automated insight into the business risks of your software releases–transforming testing from a roadblock to a catalyst for innovation. The result is accelerated software delivery speed, improved cost efficiency, and reduced business risk.
Tricentis is the only vendor to achieve “Leader” status in all three top analyst reports (i.e., the “Triple Crown”). This honor is based on our technical leadership, innovation, and a Global 2000 customer base of 1600+ companies, including global enterprises such as Allianz, ANZ Bank, Cisco, Dolby, Experian, First Data, HSBC, Merck, Office Depot, Samsung, Swiss Re, Starbucks, Telstra, UBS, Vodafone, Whole Foods, and WorldPay. Customers rely on Tricentis to achieve and sustain test automation rates of over 90 percent–increasing risk coverage while accelerating testing to keep pace with Agile and DevOps.
Tricentis has a global presence in Austria, Australia, Belgium, Denmark, Germany, India, Netherlands, Singapore, Switzerland, Poland, United States and the UK. To learn more, visit https://www.tricentis.com or follow us on LinkedIn , Twitter , and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200115005741/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom